Serum complement C3 levels are associated with nonalcoholic fatty liver disease independently of metabolic features in Chinese population

Chengfu Xu1,*, Yi Chen1,*, Lei Xu1,2, Min Miao3, Youming Li1 & Chaohui Yu1

Serum complement C3 levels are closely associated with obesity and related metabolic disorders. This study aimed to investigate the association between serum complement C3 levels with non-alcoholic fatty liver disease (NAFLD). A cross-sectional study was performed among adults who took their annual health examinations at Zhenhai Lianhua Hospital, Ningbo, China during 2014. We included 7540 participants (5069 men and 2471 women) in this study. NAFLD patients had higher serum complement C3 levels ($P < 0.001$), and these levels were positively associated with both NAFLD prevalence and severity ($P < 0.001$). The above association remains true among lean and metabolic syndrome-free participants. Multivariable regression analysis showed that serum complement C3 was independently associated with risk for NAFLD (OR $= 5.231; 95\%$ CI: 3.169–8.635). Serum complement C3 level is positively associated with prevalence and severity of NAFLD, and this association is independent of obesity and metabolic syndrome.

Nonalcoholic fatty liver disease (NAFLD) is one of the most epidemic chronic liver diseases worldwide and emerging as a major public health problem globally in recent years. The prevalence of NAFLD is approximately 20% in general population and up to about 70% in patients with type 2 diabetes1. NAFLD represents a spectrum of liver diseases, including simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis2. Simple steatosis is considered to be benign with slow exacerbation over decades, whereas NASH can progress to cirrhosis, liver failure and even hepatocellular carcinoma in a relatively short period of time3.

Obesity is a major risk factor of NAFLD and increase in body weight is a main drive for high prevalence of NAFLD4–6. Weight reduction is proved to be beneficial in NAFLD treatment, with improvement in serum liver enzyme and liver histopathology7. Recent studies reported that NAFLD is also commonly detected in non-obese individuals8–10, suggesting that, besides obesity, other factors may contribute to development of NAFLD.

Complement system is increasingly recognized to be closely associated with obesity and related metabolic disorders11, and may be involved in NAFLD. In an observational study conducted in Netherland, activation of complement system was observed in 74% of 43 NAFLD patients12. In another cohort of 523 subjects with (an increased risk of) type 2 diabetes and cardiovascular diseases, serum complement C3a levels were observed to be positively associated with liver fat content13. A recent relatively large population study in China also found that participants with higher serum complement C3 levels are more likely to have NAFLD than those with low C3 levels14. However, whether the association between serum complement C3 levels or NAFLD is independent of obesity and metabolic syndrome remains not certain, neither is the link between serum C3 levels and severity of NAFLD.

Herein, we performed a cross-sectional study to investigate the association of serum C3 levels with prevalence and severity of NAFLD in a large Chinese population.

1Department of Gastroenterology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. 2Department of Gastroenterology, Ningbo First Hospital, Ningbo, China. 3Department of Internal Medicine, Zhenhai Lianhua Hospital, Ningbo, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to Y.L. (email: xiaofu@zju.edu.cn) or C.Y. (email: ych623@sina.com)
Methods

Study population. This study was performed among adults who took their annual health examinations at Zhenhai Lianhua Hospital, Ningbo, China during 2014. We excluded the following participants: (1) those with alcohol consumption greater than 140 g/week for men and 70 g/week for women; (2) those with history of viral hepatitis, autoimmune hepatitis, or other forms of chronic liver disease; (3) those with self-reported acute infection within 2 weeks; and (4) those with body mass index less than 18.0 kg/m². A total of 7540 participants (5069 men and 2471 women) were enrolled in this study. The study protocol was approved by the Hospital Ethics Committee and performed in accordance with Declaration of Helsinki. All persons gave their informed consent prior to their inclusion in the study.

Clinical evaluations. Clinical evaluations were performed according to procedures as previously described. In brief, demographic data, medical history, and health habits were recorded by trained physicians. Standing height and body weight without shoes and with light clothes were measured in standard procedures. Body mass index was calculated as body weight (kg) divided by square of height (meters). Waist circumference was measured at the level of the narrowest point between the iliac crest and the rib cage using a non-stretchable tape. Systolic and diastolic blood pressures were measured using an automated sphygmomanometer, with participants in sitting position.

Overnight fasting blood samples were obtained from each participant, and serum samples were separated for biochemical analysis after freezing. The biochemical values, including liver enzymes, serum lipids, glucose, and uric acid, were measured by a Hitachi 7600 autoanalyzer (Hitachi, Tokyo, Japan) using standard protocols. Serum complement C3 levels were assessed using immune-turbidimetric assay by a Hitachi 7600 autoanalyzer (Hitachi) using standard methods. The coefficients of variation were 4.5% and 6.6% for inter-assay and intra-assay, respectively.

Definition of NAFLD and metabolic syndrome. NAFLD was determined by hepatic ultrasound examination following exclusion of excessive alcohol consumption, viral, or autoimmune liver disease. Hepatic ultrasound examinations were carried out by trained ultrasonographers using a Toshiba Nemio 20 sonography machine with a 3.5-MHz probe (Toshiba, Tokyo, Japan). The ultrasonographers were blinded to the study design and clinical data. The criteria for ultrasonic diagnosis of fatty liver were based on those recommended by the Chinese Liver Disease Association.

Metabolic syndrome was defined as participant who has three or more abnormality of the following criteria recommended by new International Diabetes Federation: (1) central obesity, defined as waist circumference ≥90 cm for Chinese men and ≥80 cm for Chinese women; (2) raised triglyceride level, defined as triglycerides ≥1.70 mmol/L or specific treatment for this lipid abnormality; (3) reduced HDL-C level, defined as HDL-C <1.03 mmol/L for men and <1.29 mmol/L for women; (4) raised blood pressure, SBP ≥130 mmHg or DBP ≥85 mmHg, or treatment of previously diagnosed hypertension; and (5) raised FPG, defined as FPG ≥5.60 mmol/L or previously diagnosed type 2 diabetes.

Statistics analysis. We performed statistical analyses using SPSS 18.0 software for Windows (SPSS Inc., Chicago, IL). We expressed continuous variables as mean and standard deviation or median and interquartile range, and compared through using Student’s t-test or Mann-Whitney U test. We compared categorical variables using chi-square test. We applied a multiple stepwise regression analysis (backward: Wald; cutoff for entry: 0.05, for removal: 0.10) to assess the risk factors for NAFLD. We considered a 2-tailed P value less than 0.05 to be statistically significant.

Results

Serum complement C3 levels are elevated in participants with NAFLD. Of 7540 participants enrolled in this study, 2070 (27.45%) had NAFLD. The clinical characteristics of participants with or without NAFLD were presented in Table 1. We found that participants with NAFLD were older, male predominant, and with higher body mass index, waist circumference, systolic and diastolic blood pressure than those without NAFLD (Table 1). We also found participants with NAFLD had significantly higher serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase, albumin, triglyceride, total cholesterol, LDL cholesterol, fasting blood sugar, uric acid, white blood cell, and platelet count, while lower serum HDL cholesterol levels than those without NAFLD (all with P < 0.001; Table 1). A noticeable finding is that serum complement C3 levels were significantly higher in participants with NAFLD than those without NAFLD, suggesting a potential link between serum complement C3 levels with NAFLD (Table 1).

Serum complement C3 levels are positively associated with prevalence and severity of NAFLD. To further clarify the association of serum complement C3 levels with NAFLD, we divided all participants into quartiles according to their serum complement C3 levels: <1.07 g/L, 1.07–1.16 g/L, 1.17–1.26 g/L, and ≥1.27 g/L for quartile 1, 2, 3, and 4, respectively. We found a positive correlation between serum complement C3 quartiles and NAFLD prevalence. The prevalence was 7.8% among participants with serum complement C3 in the first quartile, and increased to 19.45%, 31.56%, and 49.41%, in quartiles 2, 3, and 4, respectively (P for trend <0.001; Table 2). This finding suggests that participants with higher serum complement C3 quartiles are more likely to have NAFLD.

We also analyzed the association between serum complement C3 levels and severity of NAFLD. Individuals with ultrasonographic hepatosteatosis combined with abnormal liver enzymes are considered to be a more severe form of NAFLD. Therefore, we divided NAFLD patients into two groups according to whether their serum ALT levels were elevated (≥50 U/L) or not. We found that the medium (interquartile range) of serum complement C3 levels was 1.25 (1.16–1.36) g/L in NAFLD patients with normal range of serum ALT, but the levels
with disease severity. These findings suggest that serum complement C3 levels were not only associated with NAFLD prevalence, but also associated for trend ($P<0.001$). These results indicate that the link between serum complement C3 and NAFLD is independent of obesity and obesity-related metabolic disorders.

NAFLD patients compared with those without (1.24 (1.15–1.33) g/L vs. 1.12 (1.04–1.22) g/L, $P<0.001$). A positive correlation between serum complement C3 levels and prevalence of NAFLD was also observed among lean and metabolic syndrome-free participants. The prevalence was 3.55%, 10.54%, 16.97%, and 29.66%, in quartiles 1, 2, 3, and 4, respectively ($P<0.001$).

The association between serum complement C3 and NAFLD is independent of obesity and metabolic syndrome. Obesity and metabolic syndrome are two major factors that closely associate with NAFLD, and these two factors may act as cofactors for the link between serum complement C3 levels and NAFLD. To explore whether the link between serum complement C3 levels and NAFLD is independent of obesity and metabolic syndrome, we excluded 2383 participants who were obese (BMI $\geq$ 25 kg/m$^2$) and/or had metabolic syndrome. Of the remaining 5157 lean and metabolic syndrome-free participants, 693 (13.43%) met diagnostic criteria of NAFLD. Serum complement C3 levels remained to be significantly higher in NAFLD patients compared with those without (1.24 (1.15–1.33) g/L vs. 1.12 (1.04–1.22) g/L, $P<0.001$). A positive correlation between serum complement C3 levels and prevalence of NAFLD was also observed among lean and metabolic syndrome-free participants. The prevalence was 0.43%, 1.53%, 4.62%, and 10.63% in quartiles 1, 2, 3, and 4, respectively ($P<0.001$). These findings suggest that serum complement C3 levels were not only associated with NAFLD prevalence, but also associated with disease severity.

### Table 1. Characteristics of study participants with or without NAFLD. Data are expressed as mean (SD) or median (IQR). $^a$χ$^2$ value; $^b$Z value; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

| Variables | With NAFLD | Without NAFLD | t value | P value |
|-----------|------------|---------------|---------|---------|
| n (male/female) | 2070 (1623/447) | 5470 (3446/2024) | 161.810$^a$ | <0.001 |
| Age (year) | 51.0 (14.2) | 48.4 (15.6) | 6.376 | <0.001 |
| Body mass index (kg/m$^2$) | 25.67 (2.70) | 22.46 (2.43) | 49.770 | <0.001 |
| Waist circumference (cm) | 88.7 (8.1) | 80.5 (8.0) | 39.422 | <0.001 |
| Systolic blood pressure (mmHg) | 129.7 (14.9) | 122.3 (16.0) | 18.269 | <0.001 |
| Diastolic blood pressure (mmHg) | 80.0 (9.6) | 75.1 (9.5) | 19.768 | <0.001 |
| Alanine aminotransferase (U/L) | 26.0 (19.0–41.0) | 16.0 (12.0–22.0) | 34.604$^b$ | <0.001 |
| Aspartate aminotransferase (U/L) | 24.0 (20.0–30.0) | 20.0 (17.0–24.0) | 21.571$^b$ | <0.001 |
| γ-Glutamyltransferase (U/L) | 32.0 (23.0–49.0) | 19.0 (15.0–27.0) | 34.085$^b$ | <0.001 |
| Triglyceride (mmol/L) | 1.60 (1.18–2.22) | 0.97 (0.71–1.34) | 36.384$^b$ | <0.001 |
| Total bilirubin (μmol/L) | 14.8 (6.2) | 14.6 (6.6) | 1.729 | 0.084 |
| Albumin (g/L) | 47.1 (2.6) | 46.6 (2.7) | 6.699 | <0.001 |
| Total cholesterol (mmol/L) | 5.03 (4.44–5.71) | 4.75 (4.15–5.40) | 11.976$^b$ | <0.001 |
| HDL cholesterol (mmol/L) | 1.42 (1.25–1.61) | 1.62 (1.43–1.88) | 25.196$^b$ | <0.001 |
| LDL cholesterol (mmol/L) | 2.81 (0.76) | 2.60 (0.77) | 10.312 | <0.001 |
| Fasting plasma glucose (mmol/L) | 5.10 (4.73–5.60) | 4.90 (4.60–5.27) | 13.943$^b$ | <0.001 |
| Platelet count (×10$^9$/L) | 215.0 (184.0–250.0) | 209.0 (178.0–242.0) | 5.231; 95% CI: 3.169–8.635 | <0.001 |
| White blood cell (×10$^9$/L) | 6.4 (5.5–7.5) | 5.7 (4.9–6.7) | 19.846$^b$ | <0.001 |
| Serum uric acid (μmol/L) | 376.5 (80.5) | 317.9 (77.0) | 29.126 | <0.001 |
| Total bilirubin (μmol/L) | 14.8 (6.2) | 14.6 (6.6) | 1.729 | 0.084 |
| HDL cholesterol (mmol/L) | 1.42 (1.25–1.61) | 1.62 (1.43–1.88) | 25.196$^b$ | <0.001 |
| LDL cholesterol (mmol/L) | 2.81 (0.76) | 2.60 (0.77) | 10.312 | <0.001 |
| Fasting plasma glucose (mmol/L) | 5.10 (4.73–5.60) | 4.90 (4.60–5.27) | 13.943$^b$ | <0.001 |
| Platelet count (×10$^9$/L) | 215.0 (184.0–250.0) | 209.0 (178.0–242.0) | 5.085$^b$ | <0.001 |
| Serum complement C3 (g/L) | 1.26 (1.17–1.37) | 1.13 (1.04–1.23) | 17.699 | <0.001 |

### Table 2. Association of serum complement C3 levels with prevalence rate of NAFLD. PR%, prevalence rate; PR, prevalence ratio.

| Complement C3 quartiles | Total | NAFLD | PR% | PR | $\chi^2$ | P value |
|-------------------------|-------|-------|-----|----|---------|---------|
| Quartile 1              | 1459  | 145   | 7.78| 1.00|         |         |
| Quartile 2              | 1474  | 368   | 19.45| 2.50|         |         |
| Quartile 3              | 1502  | 555   | 31.56| 4.06|         |         |
| Quartile 4              | 1481  | 1004  | 49.41| 6.35| 1170.393| <0.001  |

Elevated serum complement C3 levels independently increases risk of NAFLD. We further performed a stepwise multiple regression analysis, to explore whether elevated serum complement C3 levels was independently associated with increased risk for NAFLD. We input 17 variables including age, gender, body mass index, waist circumference, systolic and diastolic blood pressure, ALT/AST, γ-glutamyltransferase, albumin, triglyceride, total cholesterol, HDL cholesterol, fasting blood sugar, serum uric acid, white blood cell, platelet count, and serum complement C3 into the original equation. We found that 16 variables remained in the final equation and predicted to be closely associated with risk for NAFLD (Table 3). A noticeable finding was that serum complement C3 was significantly associated with risk for NAFLD (OR = 5.231; 95% CI: 3.169–8.635). This finding increased to 1.33 (1.23–1.46) g/L in NAFLD patients with elevated serum ALT (Mann-Whitney U test, $P<0.001$). We also found that the prevalence of NAFLD with elevated serum ALT, a more severe form of NAFLD, was positively correlated with serum complement C3 levels. The prevalence was 0.43%, 1.53%, 4.62%, and 10.63% in participants with serum complement C3 in quartiles 1, 2, 3, and 4, respectively ($P$ for trend $<0.001$). These findings suggest that serum complement C3 levels were not only associated with NAFLD prevalence, but also associated with disease severity.
Scientific Reports | 6:23279 | DOI: 10.1038/srep23279

Table 3. Risk factors associated with the presence of NAFLD. β, partial regression coefficient; SE, standard error of partial regression coefficient; OR, odds ratio; CI, confidence interval; HDL, high-density lipoprotein.

| Variables                          | β     | SE   | Wald χ² | P      | OR (95% CI)       |
|------------------------------------|-------|------|---------|--------|-------------------|
| Age (year)                         | 0.028 | 0.003| 79.970  | <0.001 | 1.028 (1.022–1.035) |
| Male gender                        | 0.549 | 0.106| 26.884  | <0.001 | 1.731 (1.407–2.129) |
| Body mass index (kg/m²)            | 0.284 | 0.018| 248.144 | <0.001 | 1.328 (1.282–1.376) |
| Waist circumference (cm)           | 0.039 | 0.006| 41.316  | <0.001 | 1.040 (1.028–1.053) |
| Diastolic blood pressure (mmHg)    | 0.025 | 0.005| 28.278  | <0.001 | 1.025 (1.016–1.034) |
| ALT/AST ratio                      | 1.649 | 0.107| 235.661 | <0.001 | 5.201 (4.213–6.419) |
| γ-Glutamyltransferase (U/L)        | 0.005 | 0.001| 18.993  | <0.001 | 1.005 (1.003–1.008) |
| Albumin (g/L)                      | 0.081 | 0.015| 30.619  | <0.001 | 1.084 (1.054–1.116) |
| Triglyceride (mmol/L)              | 0.214 | 0.055| 15.234  | <0.001 | 1.238 (1.112–1.379) |
| Total cholesterol (mmol/L)         | 0.156 | 0.049| 9.944   | <0.002 | 1.169 (1.061–1.288) |
| HDL cholesterol (mmol/L)           | 1.352 | 0.171| 62.530  | <0.001 | 0.259 (0.185–0.362) |
| Fasting plasma glucose (mmol/L)    | 0.123 | 0.034| 12.925  | <0.001 | 1.131 (1.058–1.209) |
| Serum uric acid (μmol/L)           | 0.003 | 0.001| 44.775  | <0.001 | 1.003 (1.002–1.004) |
| White blood cell (<10^9/L)         | 0.064 | 0.024| 6.923   | <0.009 | 1.066 (1.016–1.118) |
| Platelet count (<10^12/L)          | 0.003 | 0.001| 20.754  | <0.001 | 1.003 (1.002–1.005) |
| Serum complement C3 (g/L)          | 1.655 | 0.256| 41.869  | <0.001 | 5.231 (3.169–8.635) |

This cross-sectional study revealed that NAFLD patients had higher serum complement C3 levels, which in further analysis turned out to be positively associated with both NAFLD prevalence and severity. This relationship was independent of age, gender, body mass index, waist circumference, systolic and diastolic blood pressure, ALT/AST, γ-glutamyltransferase, uric acid and other metabolic syndrome features. Serum complement C3 levels are observed to be independently associated with dyslipidemia, coronary heart disease, diabetes, and hypertension. In this study, we provided evidences for the first time that serum complement C3 level is independently associated with NAFLD in non-obese and metabolic syndrome free population, and the C3 levels are positively associated with severity of NAFLD. Our results suggested a significant role of complement C3 in NAFLD.

The underlying mechanism by which complement C3 interacts with NAFLD remained unknown, but several hypotheses were proposed. Firstly, complement components, particularly C3, play important role in lipid metabolism. C3 is mainly synthesized in hepatocytes but can also be secreted by adipose tissue and recently discovered to be present in lipoprotein particles, such as high density lipoprotein and chylomicron. C3 knockout mice had 58% higher serum triglyceride levels and altered lipoprotein profile with more low-density lipoprotein cholesterol and very-low-density lipoprotein triglycerides, indicating a potential role of C3 in lipid metabolism regulation. Secondly, innate immune response is a part of the most widely accepted theory of NAFLD pathogenesis, "two hit model". The first hit is correlated with insulin resistant with fat accumulation and then on this basis, oxidative stress induces varied inflammatory cytokines as well as great number of adipokines, inducing the second hit. Complement system, as a major player in innate immune response, might be activated by the first hit and forming the second hit in NAFLD pathogenesis. The third, hepatocyte apoptosis, activated by intracellular stress of membrane-bound organelles and molecule cascade including caspases 3 and 7, or cleavage of cytokeratin 18, is a key morphologic and pathogenic feature of human NAFLD and NASFH. Complement system was found to be activated by apoptosis and can help with recognition and clearance of apoptotic cells. Thus elevation of serum complement C3 might act as a protective response in NAFLD mediated by apoptosis. Last but not least, acylation-stimulating protein (ASP), a C3 derivative involved in adipocyte lipid metabolism by stimulating triglyceride synthesis, was found increased in NAFLD patients. On one hand, this was considered as a result from "ASP resistance" of adipose tissue in NAFLD patients, but on the other hand, hepatic C3 activation can also be the trigger. ASP can promote triglyceride accumulation in liver cells; thereby forming a vicious cycle that complement activation exacerbates steatosis, and in return steatosis promotes complement activation.

Our study has some limitations. Firstly, although ultrasound-based diagnosis of NAFLD is widely accepted under clinical circumstances as a noninvasive cost-effective screening for NAFLD with sensitivity of 89% and specificity of 93%, it cannot replace pathological study as gold standard in disease diagnosis. Further explore the relationship between serum C3 levels and histological severity of NAFLD would be of great interest. Secondly, with the nature of cross-sectional study, no causal relationship can be identified. Further prospective studies are needed in this concern. Nevertheless, current analysis revealed that serum complement C3 is positively associated with prevalence of NAFLD and disease severity as well.

Our study has significant importance for NAFLD therapy and prevention. C3, as a key in innate immune system and potential regulator of lipid metabolism as mentioned above, may contribute significantly to pathogenesis.
of NAFLD. Thus, developing medication targeting C3/C3 receptor or intervening C3 activation might be effective for NAFLD treatment. Moreover, high serum C3 levels can also serve as an independent predictor for NAFLD. With well-established relationship between C3 and NAFLD prevalence as well as disease severity, in addition to the role of potential therapeutic target, prognostic role of C3 is also worth investigating.

In conclusion, current cross-sectional study in a large Chinese population revealed that serum complement C3 level is positively associated with prevalence and severity of NAFLD, and this association is independent of obesity and metabolic syndrome.

References

1. Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142, 1592–1609 (2012).
2. Sattar, N., Forrest, E. & Preiss, D. Non-alcoholic fatty liver disease. BMJ 349, g4596 (2014).
3. Starley, B. Q., Calcagno, C. J. & Harrison, S. A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51, 1820–1832 (2010).
4. Church, T. S. et al. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 130, 2023–2030 (2006).

5. Omagari, K. et al. Predictive factors for the development or regression of fatty liver in Japanese adults. Journal of clinical biochemistry and nutrition 45, 56 (2009).
6. Miyake, T. et al. Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study. Journal of gastroenterology 48, 413–422 (2013).
7. Peng, L., Wang, J. & Li, F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev, CD003619 (2011).
8. Younossi, Z. M. et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 91, 319–327 (2012).
9. Xu, C. et al. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol 108, 1299–1304 (2013).
10. Kim, N. H. et al. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver Int 34, 604–611 (2014).
11. Bertle, E., Stehouwer, C. D. & van Greevenbroek, M. M. The complement system in human cardiometabolic disease. Mol Immunol 61, 135–148 (2014).
12. Rensen, S. S. et al. Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology 50, 1809–1817 (2009).
13. Wlazlo, N. et al. Activated complement factor 3 is associated with liver fat and liver enzymes: the CODAM study. Eur J Clin Invest 43, 679–688 (2013).

14. Jia, Q. et al. Association between Complement C3 and Prevalence of Fatty Liver Disease in an Adult Population: A Cross-Sectional Study from the Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIHealth) Cohort Study. PLoS One 10, e0122026 (2015).
15. Yu, C. et al. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol 56, 241–247 (2012).
16. Fan, J. G. et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010. J Dig Dis 12, 38–44 (2011).
17. Alberti, K. G., Zimmet, P. & Shaw, J. Metabolic syndrome–a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23, 469–480 (2006).
18. Lazo, M. et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 343, d6891 (2011).
19. Onat, A., Can, G., Rezvani, R. & Gianfalone, F. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta 412, 1171–1179 (2011).
20. Barbu, A., Hamad, O. A., Lind, L., Ekdhäi, K. N. & Nilsson, B. The role of complement factor C3 in lipid metabolism. Mol Immunol 67, 101–107 (2015).

21. Mussa, A. et al. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 24, 1081–1090 (2000).
22. Onat, A. et al. Cross-sectional study of complement C3 as a coronary risk factor among men and women. Clin Sci (Lond) 108, 129–135 (2005).
23. van Greevenbroek, M. M. et al. Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM study). Int J Cardiol 154, 158–162 (2012).
24. Engstrom, G., Hedblad, B., Eriksson, K. F., Janzon, L. & Lindgarde, F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 54, 570–575 (2005).
25. Zhou, X. et al. Complement 3 activates the renal renin-angiotensin system by induction of epithelial-to-mesenchymal transition of the nephrotubulus in mice. Am J Physiol Renal Physiol 305, F957–967 (2013).
26. Vaisar, T. et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117, 746–756 (2007).
27. Choy, L. N., Rosen, B. S. & Spiegelman, B. M. Adipins and an endogenous pathway of complement from adipose cells. J Biol Chem 267, 12736–12741 (1992).
28. Persson, L. et al. Lack of complement C3/C3 receptor, but not factor B, increases hyperlipidaemia and atherosclerosis in apolipoprotein E−/− low-density lipoprotein receptor−/− mice. Arterioscler Thromb Vasc Biol 24, 1062–1067 (2004).
29. Brun, E. M. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7, 199–203 (2010).
30. Meli, R., Mattace Raso, G. & Calignano, A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 5, 177 (2014).
31. Malhi, H. & Gores, G. J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Seminars in liver disease 28, 360 (2008).
32. Ogden, C. A. et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macrophagocytosis and uptake of apoptotic cells. J Exp Med 194, 781–795 (2001).
33. Yesilova, Z. et al. Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. Am J Gastroenterol 100, 842–849 (2005).
34. Joseph, A. E., Sarevymuttu, S. H., al-Sam, S., Cook, M. G. & Maxwell, J. D. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 43, 26–31 (1991).
35. Angulo, P. Nonalcoholic fatty liver disease. N Engl J Med 346, 1221–1231 (2002).

Acknowledgements

This work was supported by National Key Basic Research Development Program (No. 2012CB524905 to Y.L.), National Science and Technology Support Project (No. 2012BAI06B04 to Y.L.), National Natural Science Foundation of China (Nos 81100278 and 81470838 to C.X., 81300703 to L.X., 81170378 and 81230012 to Y.L.)
and 81270487 to C.Y.), Zhejiang Provincial Natural Science Foundation of China (Nos LR15H030001 to C.X. and LY13H030012 to L.X.), International Science and Technology Cooperation Projects of Zhejiang Province (No. 2013C24010 to C.X.) and Science Foundation of Health Bureau of Zhejiang Province (No. 2012RCA026 to C.X.). The funders did not play any role in the study design, data collection and analysis, decisions regarding data release or manuscript preparation.

Author Contributions
C.X. and Y.C. proposed with the initial idea and designed the study. C.X., M.M. and L.X. conducted the procedures. C.Y. and Y.L. supervised and provided consult during the whole study.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Xu, C. et al. Serum complement C3 levels are associated with nonalcoholic fatty liver disease independently of metabolic features in Chinese population. Sci. Rep. 6, 23279; doi: 10.1038/srep23279 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/